Chemical formula: C₁₃H₁₀FN₃ Molecular mass: 227.242 g/mol PubChem compound: 44139752
Osilodrostat is a cortisol synthesis inhibitor. It potently inhibits 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In Cushing’s disease, the fall in plasma cortisol concentration also stimulates ACTH secretion, via the feedback mechanism which accelerates steroid biosynthesis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| H02CA02 | H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02C Antiadrenal preparations → H02CA Anticorticosteroids | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ISTURISA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ISTURISA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Osilodrostat is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Israel (IL)
Italy (IT)
Japan (JP)
Lithuania (LT)
Poland (PL)
Romania (RO)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
